MedTrace Logo

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

NCT00396448 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1253

Last updated 2012-11-07

No results posted yet for this study

Summary

The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

Conditions

Interventions

DRUG

CP-945,598 Treatment B

Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.

DRUG

CP-945,598 Treatment A

Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.

DRUG

Placebo

Subjects receive placebo plus dietary, physical activity, and behavioral counseling.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States
  • Argentina
  • Australia
  • Chile
  • France
  • Germany
  • Mexico
  • South Korea
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00396448 on ClinicalTrials.gov